Tolling/White Labeling Service was IGC Pharma’s largest product and service line in fiscal 2025, bringing in $1.16M of $1.27M (91%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trading | — | — | — | — | ||||||||
| Purchase & Resale Of Physical Commodities | — | — | — | — | ||||||||
| Tolling/White Labeling Service | $43.00K | $382.00K | $953.00K | $1.16M | ||||||||
| Wellness & Lifestyle | $316.00K | $416.00K | $228.00K | $113.00K | ||||||||
| Construction | $15.00K | $76.00K | — | — | ||||||||
| Other Revenue | — | — | $164.00K | — | ||||||||
| Rental/Lease | — | — | — | — | ||||||||
| Construction Contracts | — | — | — | — | ||||||||
| Plant & Cannabinoid | — | — | — | — | ||||||||
| Rental Income | $23.00K | $37.00K | — | — | ||||||||
| Total | $397.00K | $911.00K | $1.35M | $1.27M |
IGC Pharma brought in $1.27M from its two product and service lines in fiscal 2025, the year ended March 31, 2025. IGC Pharma regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $1.35M. Tolling/White Labeling Service was the largest at $1.16M (91.1%), ahead of Wellness & Lifestyle at $113.00K (8.9%).
Compared with fiscal 2024, Tolling/White Labeling Service grew 21.5% to $1.16M, while Wellness & Lifestyle fell 50.4% to $113.00K.
IGC Pharma stopped reporting Other Revenue ($164.00K in fiscal 2024), Construction ($76.00K in fiscal 2023) and Rental Income ($37.00K in fiscal 2023) as separate lines.
United States was IGC Pharma’s largest region in fiscal 2025, bringing in $1.27M of $1.27M (100%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Countries | — | — | — | — | ||||||||
| Hong Kong | — | — | — | — | ||||||||
| Revenues | — | — | — | — | ||||||||
| China | — | — | — | — | ||||||||
| United States | $329.00K | $777.00K | $1.18M | $1.27M | ||||||||
| Revenue | — | — | — | — | ||||||||
| North America | — | — | — | — | ||||||||
| India | $68.00K | $113.00K | $164.00K | — | ||||||||
| Colombia | — | $21.00K | $2.00K | $2.00K | ||||||||
| Total | $397.00K | $911.00K | $1.35M | $1.27M |
IGC Pharma brought in $1.27M from its two regions in fiscal 2025, the year ended March 31, 2025. IGC Pharma regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $1.35M. United States was the largest at $1.27M (99.8%), ahead of Colombia at $2.00K (0.2%).
IGC Pharma began breaking out Colombia in fiscal 2023, when it brought in $21.00K. IGC Pharma stopped reporting India as a separate region after fiscal 2024, when it brought in $164.00K.
Legacy Infrastructure was IGC Pharma’s largest segment in fiscal 2020, bringing in $3.55M of $3.94M (90%).
| Segment | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|
| Asia | — | $5.02M | — |
| Legacy Infrastructure | $2.09M | $30.00K | $3.55M |
| Life Sciences | — | $25.00K | $386.00K |
| Total | $2.09M | $5.08M | $3.94M |
IGC Pharma brought in $3.94M from its two segments in fiscal 2020, the year ended March 31, 2020. IGC Pharma regrouped these segments after fiscal 2019, so the total does not compare directly with that year's $5.08M. Legacy Infrastructure was the largest at $3.55M (90.2%), ahead of Life Sciences at $386.00K (9.8%).
Compared with fiscal 2019, Legacy Infrastructure grew 11,743.3% to $3.55M and Life Sciences grew 1,444.0% to $386.00K.
IGC Pharma began breaking out Life Sciences in fiscal 2019, when it brought in $25.00K. IGC Pharma stopped reporting Asia as a separate segment after fiscal 2019, when it brought in $5.02M.
IGC Pharma (IGC) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Tolling/White Labeling Service was its largest product and service line, bringing in $1.16M (91.1% of the total), followed by Wellness & Lifestyle at $113.00K (8.9%).
Tolling/White Labeling Service was IGC Pharma's largest product and service line in fiscal 2025, bringing in $1.16M, or 91.1% of the $1.27M total across its two product and service lines.
United States was IGC Pharma's largest region in fiscal 2025, bringing in $1.27M, or 99.8% of the $1.27M total across its two regions.
Legacy Infrastructure was IGC Pharma's largest segment in fiscal 2020, bringing in $3.55M, or 90.2% of the $3.94M total across its two segments.
Every figure comes from IGC Pharma's annual financial filings, as reported. Each line keeps the name IGC Pharma gives it, and years follow its fiscal calendar.
IGC Pharma's revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.